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Abstract
Objective: To determine if the use of intraoperative hemostatic agents was a risk 
factor for post- operative adverse events within 30 days of patients undergoing 
hysterectomy.
Method: A population- based retrospective cohort study included data from patients 
undergoing hysterectomy for any indication between January 1, 2013, and December 
31, 2014, at 52 hospitals in Michigan, USA. Any individuals with missing covariate data 
were excluded, and multivariable logistic regression and propensity score- matching 
were used to estimate the rate of post- operative adverse events associated with intra- 
operative hemostatic agents independent of demographic and surgical factors.
Results: There were 17 960 surgical procedures included in the analysis, with 4659 
(25.9%) that included the use of hemostatic agents. Hemostatic agent use was associ-
ated with an increase in predicted hospital re- admissions (P=0.007). Among all hyster-
ectomy approaches, and after adjusting for demographic and surgical factors, 
hemostatic agent use during robotic- assisted laparoscopic hysterectomy was associ-
ated with an increased predicted rate of blood transfusions (P=0.019), an increased 
predicted rate of pelvic abscess diagnoses (P=0.001), an increased predicted rate of 
hospital re- admission (P=0.001), and an increased predicted rate of re- operation 
(P=0.021).
Conclusion: Hemostatic agents should be used carefully owing to associations with 
increased post- operative re- admissions and re- operations when used during 
hysterectomy.
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1  | INTRODUCTION
Excessive bleeding during surgery, and subsequent need for blood 
transfusion, is one of the commonest major adverse events across all 
surgeries.1 In the management of intra- operative bleeding, hemosta-
sis can be achieved using manual pressure, suture ligation, electro- 
cautery, ultrasonic coagulation, laser ablation, staples and clips, or the 
application of hemostatic products. Combinations of these are often 
employed in surgery; however, there is limited knowledge regarding 
the comparative effectiveness of these methods across every surgical 
procedure.
Hemostatic agents have been used widely in surgery and their use is 
increasing; of 430 000 hysterectomies performed in the USA in 2010, 
hemostatic agents were utilized in 14% of procedures—approximately 
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60 000 hysterectomies.2,3 However, there is a paucity of data sup-
porting the routine use of hemostatic agents during hysterectomy to 
reduce the need for post- operative transfusions beyond traditional 
mechanical and electric- cautery techniques. Further, these agents 
add costs to each procedure and could be associated with adverse 
events requiring hospital re- admission, antibiotic administration, and 
re- operation.4–11
Therefore, the aim of the present study was to estimate, among 
patients undergoing hysterectomy, the effect of hemostatic agents 
on post- operative blood transfusion rates, pelvic abscess diagnoses, 
hospital re- admissions, and re- operations.
2  | MATERIALS AND METHODS
A retrospective cohort study included data from the Michigan Surgical 
Quality Collaborative (MSQC) database, a large, observational, 
multi- center clinical database of surgical and post- operative care in 
Michigan, USA. Data in the MSQC database from patients who un-
derwent a hysterectomy for any indication between January 1, 2013 
and December 31, 2014 were included in the study; patient data 
were excluded if there were any missing covariate data. The study 
included de- identified patient records and the University of Michigan 
institutional review board granted “Not Regulated” status to the study 
(HUM00073978).
The MSQC is a Blue Cross Blue Shield of Michigan/Blue Care 
Network- funded database voluntarily populated by both academic 
and community hospitals throughout Michigan, USA. At the time the 
present study was conducted, data from 52 participating hospitals 
were available for analyses. At each site, data were abstracted from 
medical records by trained nurse abstractors. Patient characteristics, 
intra- operative processes of care, and 30- day post- operative out-
comes from hysterectomy procedures at contributing hospitals were 
routinely collected. To reduce sampling error, a standardized data 
collection methodology was employed using only the first 25 surgical 
procedures of an 8- day cycle. Detailed methods of the registry’s data 
collection have been described previously.12,13
The primary outcome variable was the presence of the major 
post- operative adverse events blood transfusion, diagnosis of pelvic 
abscess, hospital re- admission, and re- operation within 30 days of 
initial surgery. Post- operative blood transfusion was defined as the 
transfusion of any number of packed red blood cells after the primary 
surgery. Post- operative hospital readmission was defined as an inpa-
tient hospital re- admission. Pelvic abscess diagnosis was defined as 
a surgical site infection in the organ space recorded in the patient’s 
medical records. Post- operative re- operation was defined as any post- 
operative surgical operation for any indication, other than the comple-
tion of cancer staging.
The primary independent variable was the use of a hemostatic 
agent (oxidized cellulose polymer, thrombin- containing gelatin matrix, 
absorbable gelatin compressed sponge, or hemostatic agent of un-
known type), as recorded in the operative notes. Owing to the overlap 
in the usage of these products and the high rate of hemostatic agent 
usage without specifically identifying the agent, associations between 
individual products and major post- operative adverse events were not 
analyzed. Patients were only identified as having received of not re-
ceived a hemostatic agent.
The patient and surgical characteristics include in the analyses as 
covariates were age, race, body mass index, surgical indication (can-
cer, uterine fibroids, or other), surgical approach (abdominal, laparo-
scopic non- robotic- assisted, robotic- assisted, or vaginal), estimated 
blood loss, measured uterine specimen weight, and surgical time. To 
help control for confounding by the complexity of surgical procedures, 
the total relative value units (based on current procedural terminology 
codes) were calculated for the total concurrent operative procedures. 
Finally, overall patient comorbidity was measured using a modified 
Charlson comorbidity score.14
Descriptive statistics were analyzed using the χ2 test for categor-
ical variables and confidence intervals (CIs) were calculated using the 
Wilson score interval for binomial distributions. Multivariable logistic 
regression including the covariates described above and propensity 
score matching was performed to isolate associations between he-
mostatic agent use and post- operative adverse events. The regression 
model included an interaction term between hemostatic agent use 
and surgical approach. All variables were analyzed as continuous vari-
ables except for surgical indication and approach, which were analyzed 
as categorical variables. The propensity score was calculated using the 
covariates detailed above.
The matched cohort included a 1:2 ratio between patients who 
received hemostatic agents and those who did not; a 0.1- unit caliper 
width was used as a replacement. Average effects were reported in 
terms of predicted outcome probabilities with the presence or ab-
sence of hemostatic agents, with all other covariates maintained at 
their observed values because effect sizes could not be inferred di-
rectly from coefficients or odds ratios of logit models. Two- tailed 
hypothesis testing was performed and P<0.05 was considered statis-
tically significant. STATA version 13.1 (StataCorp LP, College Station, 
Texas, USA) was used for all analyses.
3  | RESULTS
There were 18 302 hysterectomies recorded during the study period; 
202 (1.1%) were excluded because the surgeries were not performed 
by a gynecologist and 140 (0.8%) were excluded owing to incom-
plete covariate data. Consequently, the full study cohort included 
13 301 patients who did not receive hemostatic agents and 4659 
who did (Fig. 1). There were 13 974 patients included in the pro-
pensity score matched cohort, including 9316 (66.7%) patients who 
did not receive a hemostatic agent and 4658 (33.3%) patients who 
did. Among the full study cohort, patients who received hemostatic 
agents were more likely have fibroids (P<0.001), to have undergone 
robotic surgery (P<0.001), and to experience an estimated blood loss 
of at least 250 mL (P<0.001). After propensity score matching, the 
cohort was found to be closely matched across all characteristics 
(Table 1).
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The overall prevalence of post- operative blood transfusion was 
2.7% (95% CI 2.5–3.0). The logistic regression model demonstrated 
no association between the use of hemostatic agents and the pre-
dicted prevalence of blood transfusion (P=0.291) (Table 2). This was 
consistent with the estimate from the propensity score matched 
cohort (P=0.764).
The overall prevalence of pelvic abscess was 1.0% (95% CI 0.9–
1.2) and no association was observed between hemostatic agent use 
and the incidence of pelvic abscesses in either the logistic regression 
variable model (P=0.144) or the propensity score matched cohort 
(P=0.188) analyses.
The rate of hospital re- admissions across the complete cohort was 
4.0% (95% CI 3.7–4.3). The most common re- admission diagnoses 
were related to infection and hematoma. Both the logistic regression 
variable model (P=0.047) and the propensity score matched cohort 
(P=0.007) found that the use of hemostatic agents was associated 
with increases in post- operative hospital re- admission.
Re- operations were performed for 2.1% (95% CI 1.9–2.3) of surgi-
cal patients during the study period. The most common surgical indi-
cation for re- operation was hemorrhage or hematoma. No association 
was observed between the application of hemostatic agents and re-
quiring post- operative re- operation in the logistic regression variable 
model (P=0.075) or propensity score matched cohort (P=0.090).
The outcomes of interest were also analyzed in terms of the sur-
gical approach used during hysterectomy. Among surgeries performed 
using vaginal and abdominal approaches, no differences were observed 
in transfusions, pelvic abscesses, re- admissions, or re- operations be-
tween patients who received hemostatic agents and those who did 
not. The use of hemostatic agents during robotic- assisted laparoscopic 
procedures was associated with a greater incidence of predicted blood 
transfusions (P=0.019), pelvic abscess diagnoses (P=0.001), hospital 
re- admissions (P=0.001), and re- operations (P=0.021) (Table 3). In lap-
aroscopic hysterectomy procedures, the use of hemostatic agents was 
associated with an increase in predicted re- admissions (P=0.045) and 
predicted re- operations (P=0.046).
4  | DISCUSSION
The present study confirmed previous findings of associations be-
tween hemostatic agents and post- operative adverse events among 
patients who have undergone hysterectomies. In this retrospective 
study that examined hysterectomies performed for any indication 
from a statewide database in the USA, no benefit was observed for 
the use of hemostatic agents in terms of reduced blood transfusions, 
and increased risks for hospital re- admission and re- operation were 
recorded when hemostatic agents were used.
Hemostatic agents are designed to improve intra- operative and 
post- operative hemostasis, decreasing surgical and post- surgical 
 adverse events such as requiring blood transfusions, the formation 
of post- operative hematomas, and re- operations.15–19 In the pres-
ent  cohort, they were used in approximately 26% of all hysterectomy 
procedures. This high rate of use suggests that they are used both to 
achieve hemostasis and as a prophylactic measure. Further, this high 
rate of utilization should be scrutinized in terms of evidence of a spe-
cific need in addition to evidence of an absence of harm. Previous 
studies supporting these benefits in hysterectomy are lacking,4–11 and 
the present analysis, confirming findings of previous studies, identified 
that these agents could be harmful.
There are multiple possible reasons why hemostatic agents could 
be associated with post- operative adverse events of hysterectomies. 
Hemostatic agents could provide inferior hemostasis in the hours 
and days following surgery compared with traditional hemostatic 
methods. Increased post- operative bleeding, even in small amounts, 
could lead to appreciable hematomas, in turn increasing the risk for 
pain through mass effects or inflammatory cytokines, or for infec-
tion by acting as a medium for the growth of bacteria; all of these 
could result in emergency department visits and re- admission.1 
Further, the presence of these foreign materials could cause per-
sistent fluid collection that eventually becomes symptomatic, lead-
ing to re- admission.6–11 Hospital re- admissions are used as a target 
for quality improvements and reimbursement oversight.20,21 Hospital 
re- admission events cost Medicare approximately US$17.4 billion in 
2004 and have been a target of performance- based repayment by 
the agency.20,21 These re- admissions and re- operations are an im-
portant, potentially avoidable outcome. Further, these findings are 
consistent with, and a reasonable extension of, previous studies of 
hemostatic agents.4–11
Previous studies in smaller cohorts have reported similar find-
ings regarding associations between hemostatic agents and pel-
vic abscesses.4,5 Anderson et al.5 found an increased risk of pelvic 
abscess after the use of a gelatin–thrombin matrix, as well as with 
F IGURE  1 Flow diagram of patient selection.
All hysterectomies 
(n=18 302)
Hysterectomies  
performed by 
gynecologists
(n=18 100)
Not performed by 
gynecologist (n=202)
Study cohort
(n=17 960)
Propensity matched 
cohort (n=13 974)
Excluded owing to 
incomplete data 
(n=140)
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oxidized regenerated cellulose. In the present study, the use of he-
mostatic agents was only associated with the diagnosis of pelvic 
abscess in robotic- assisted hysterectomies. This could result from 
a reliance on bipolar cautery and hemostatic agents to control sur-
gical bleeding, compared with a variety of methods used during 
traditional hysterectomies. Additionally, the robotic- assisted hyster-
ectomy data had the greatest statistical power and consequently, 
was better placed to detect a statistically significant result compared 
with the other analyses of individual surgical approaches. Of note, 
the causes for re- admission in the present cohort were frequently 
fever and infection. These indications for admission could be due to 
other infectious etiology, such as urinary tract infections, pneumo-
nia, or superficial surgical site infections; however, it is also possi-
ble that these more general billing codes could actually represent 
pelvic abscess symptoms. Owing to this, pelvic abscess could be a 
systematically under- attributed cause of re- admission in billing or 
nurse- abstracted data.
Hemostatic agents are used widely in gynecologic surgery and 
their use is increasing.3 In addition to their lack of proven benefit, 
these agents are expensive. In a report from one academic center in 
2014,15 the cost was identified as being between US$60 and $972 per 
agent per surgery. Assessing the benefits and harms of using hemo-
static agents is important to patients, surgeons, and payers. Further, 
the costs of re- admission significantly increase the total costs that 
could be attributed to the use of these agents.
There were limitations to the present study. Even when multivari-
able regression and propensity score matching is used, it is susceptible 
to unmeasured confounder bias, as measured and unmeasured con-
founding can cause overestimation of effect sizes. Known confounders 
were tested and controlled for but there could have been other un-
measured confounders that were not adjusted for, including surgeon 
experience, skill, or measures of hospital quality, that could have been 
associated with hospital- level use of hemostatic agents. The analyses 
attempted to control for the surgical difficulty of the procedures by 
TABLE  1 Baseline characteristics of patients undergoing hysterectomies (n=17 960).a
Characteristics
Full analytic cohort
P valueb
Propensity score matched cohort
P valueb
Hemostatic 
agents (n=4659)
No hemostatic agents 
(n=13 301)
Hemostatic 
agents (n=4658)
No hemostatic 
agents (n=9316)
Age, y <0.001 0.999
≤65 4218 (90.5) 11 729 (88.2) 4217 (90.5) 8434 (90.5)
>65 441 (9.5) 1572 (11.8) 441 (9.5) 882 (9.5)
Modified Charlson score 0.030 0.919
<4 4213 (90.4) 11 874 (89.3) 4209 (90.4) 8423 (90.4)
≥4 446 (9.6) 1427 (10.7) 449 (9.6) 893 (9.6)
Surgical indication <0.001 0.939
Cancer 482 (10.3) 1080 (8.1) 482 (10.4) 981 (10.5)
Fibroids 1608 (34.5) 3935 (29.6) 1608 (34.5) 3200 (34.3)
Other 2569 (55.1) 8286 (62.3) 2568 (55.1) 5135 (55.1)
Surgical approach <0.001 0.019
Abdominal 1317 (28.3) 2873 (21.6) 1316 (28.3) 2652 (28.5)
Laparoscopic 415 (8.9) 1646 (12.4) 415 (8.9) 847 (9.1)
Vaginal 138 (3.0) 2048 (15.4) 138 (3.0) 274 (2.9)
Laparoscopic- assisted 
vaginal
430 (9.2) 1352 (10.2) 430 (9.2) 716 (7.7)
Robotic- assisted 
laparoscopic
2359 (50.6) 5382 (40.5) 2359 (50.6) 4827 (51.8)
Operation time, h <0.001 <0.001
<3 3764 (80.8) 11 177 (84.0) 3763 (80.8) 7266 (78.0)
≥3 895 (19.2) 2124 (16.0) 895 (19.2) 2050 (22.0)
Estimate blood loss, mL <0.001 0.005
<250 3391 (72.8) 10 640 (80.0) 3391 (72.8) 6988 (75.0)
≥250 1268 (27.2) 2661 (20.0) 1267 (27.2) 2328 (25.0)
Uterine mass (measured), g <0.001 0.060
<250 3635 (78.0) 10 751 (80.8) 3635 (78.0) 7044 (75.6)
≥250 1024 (22.0) 2550 (19.2) 1023 (22.0) 2272 (24.4)
aValues are given as number (percentage) unless indicated otherwise.
bχ2 test.
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evaluating concurrent procedures being performed, operative time, 
blood loss, and uterine mass; however, this is not a completely com-
prehensive collection of all the factors that comprise surgical complex-
ity. Additionally, a key limitation of the present study was that it was 
formed from a sample of Michigan community and university hospi-
tals. It is not possible to rule out geographic variations in usage and 
this could limit the generalizability of the findings to other regions of 
the USA. Further, the exact type of hemostatic agent used was not 
well described in the data so it was not possible to break down the 
effects of individual products. Finally, data abstraction from operative 
reports could have underestimated the rate of hemostatic agent use 
and did not include information regarding important events related to 
the surgery that occurred later than 30 days after hysterectomy or any 
undocumented events that occurred outside of the primary hospital.
The present study found that the utilization of hemostatic agents 
at the time of hysterectomy was a risk factor for re- admissions and 
re- operations within 30 days of surgery in robotic and laparoscopic 
hysterectomies. The use of surgical technology should be based on the 
rigorous study of patient- centered outcomes, even when the technol-
ogy has been in use for a long period of time. In the absence of data 
TABLE  2 Estimated incidence of post- operative adverse events.
Post- operative adverse event
Multivariable logistic regression cohort (n=17 960)a Propensity score matched cohort (n=13 974)
Predicted AR (95% CI) P value Predicted AR (95% CI) P value
Post- operative blood transfusion 0.291 0.764
No hemostatic agent used 2.6 (2.4–2.9) 3.4 (2.7–3.9)
Hemostatic agent used 2.9 (2.5–3.3) 3.5 (3.0–4.1)
Post- operative pelvic abscess 0.144 0.188
No hemostatic agent used 1.0 (0.8–1.1) 1.1 (0.8–1.4)
Hemostatic agent used 1.3 (0.9–1.6) 1.4 (1.0–1.7)
Post- operative hospital re- admission 0.047 0.007
No hemostatic agent used 3.8 (3.4–4.1) 3.8 (3.4–4.3)
Hemostatic agent used 4.5 (3.9–5.1) 4.9 (4.3–5.5)
Post- operative re- operation 0.075 0.090
No hemostatic agent used 1.9 (1.7–2.2) 2.1 (1.7–2.4)
Hemostatic agent used 2.4 (1.9–2.9) 2.6 (2.1–3.0)
Abbreviations: AR, absolute rate as a percentage; CI, confidence interval.
aThe confounding variables included in the model were age, race, modified Charlson score, body mass index, surgical indication, surgical approach, 
 concurrent procedure relative value units, estimated surgical blood loss, measured uterine specimen weight, and operative length.
TABLE  3 Estimated incidence of post- operative adverse events in the propensity score cohort among different surgical approaches.
Outcome within 30 d of 
hysterectomy
Surgical approacha
Abdominal Laparoscopic
Robotic- assisted 
laparoscopic
Laparoscopic- assisted 
vaginal Vaginal
Post- operative blood transfusion
No hemostatic agent used 9.4 (8.0–10.8) 1.9 (0.8–3.0) 0.5 (0.3–0.8) 3.3 (1.8–4.8) 2.0 (0.3–3.7)
Hemostatic agent used 9.1 (7.6–10.7) 2.9 (1.2–4.5) 1.1 (0.7–1.6)b 1.4 (0.3–2.5) 1.5 (−0.5 to 3.4)
Post- operative pelvic abscess
No hemostatic agent used 1.8 (1.1–2.4) 0.7 (0.0–1.7) 0.7 (0.4–1.0) 1.2 (0.2–2.1) 2.0 (0.3–3.6)
Hemostatic agent used 1.1 (0.6–1.7) 0.7 (–0.1 to 1.5) 1.7 (1.2–2.3)c 0.7 (−0.1 to 1.5) 1.5 (−0.5 to 3.4)
Post- operative hospital re- admission
No hemostatic agent used 6.4 (5.2–7.6) 2.6 (1.3–3.8) 2.9 (2.3–2.5) 2.7 (1.3–4.1) 3.9 (1.5–6.3)
Hemostatic agent used 5.9 (4.7–7.2) 5.1 (3.0–7.2)b 4.6 (3.8–5.5)c 4.2 (2.3–6.1) 2.9 (1.0–5.7)
Post- operative re- operation
No hemostatic agent used 3.3 (2.4–4.2) 1.5 (0.5–2.5) 1.4 (0.9–1.8) 2.3 (2.0–3.6) 3.5 (1.3–5.8)
Hemostatic agent used 3.2 (2.2–4.1) 3.6 (1.8–5.4)b 2.2 (1.6–2.8)b 1.9 (0.6–3.1) 2.2 (−0.3 to 4.6)
aValues are given as predicted absolute rate (95% confidence interval).
bP<0.050.
cP≤0.001.
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demonstrating a clear benefit to their use in hysterectomy, hemostatic 
agents should be used judiciously given the possible increased risk of 
post- operative adverse events.
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